Patients with higher stage, higher T/N stage, higher tumor grade, higher Ki67, negative ER/PR status, positive HER2 status, invasive ductal carcinoma (IDC) type, and LVI would get worse survival outcomes (LRFS, DFS, and OS) (P < 0.05) (Table 3). This evidence concerns the gene ESR1 and invasive ductal breast carcinoma.